secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125351
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences reports Q3 loss $20.3M; halts PALIZADE LN trial over fatal SAEs
--------------------------------------------------------------------------------

- Net loss $20.3M ($2.78/share) vs $23.1M ($3.18) in Q3 2023; cash, equivalents and marketable securities $148.4M (Dec 31: $201.4M).
- Terminated PALIZADE Phase 2b lupus nephritis trial after 4 fatal serious adverse events; full clinical hold by FDA.
- PORTOLA autoimmune hepatitis trial: topline data expected H1 2025; IDMC recommended continue; FDA partial hold on open-label extension.
- Completed 1-for-10 reverse stock split on Oct 29, 2024 to regain $1.00 minimum bid compliance on Nasdaq.
- R&D expenses decreased to $16.2M from $23.7M; G&A to $5.7M from $8.8M due to strategic restructuring.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017024125351/0000950170-24-125351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017024125351/kzr-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer